clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.
To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with clarithromycin
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).
Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).
Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).
Model | Cross reference | Weighted score | Related literatures |
---|
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Lee KL et al. | QT prolongation and Torsades de Pointes associated with clarithromycin. | 1998 | Am. J. Med. | pmid:9576415 |
Malfertheiner P and Blum AL | [Helicobacter pylori infection and ulcer]. | 1998 | Chirurg | pmid:9576033 |
Griesgraber G et al. | Anhydrolide macrolides. 2. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbazate erythromycin A analogues. | 1998 | J. Med. Chem. | pmid:9572891 |
Elliott RL et al. | Anhydrolide macrolides. 1. Synthesis and antibacterial activity of 2,3-anhydro-6-O-methyl 11,12-carbamate erythromycin A analogues. | 1998 | J. Med. Chem. | pmid:9572890 |
Jarboe E et al. | Evaluation of a disk diffusion method for determining susceptibility of Mycobacterium avium complex to clarithromycin. | 1998 | Diagn. Microbiol. Infect. Dis. | pmid:9572027 |
Scott BB | Bismuth-containing single-antibiotic 1-week triple therapy for Helicobacter pylori eradication. | 1998 | Aliment. Pharmacol. Ther. | pmid:9570263 |
O'Connor HJ et al. | Lansoprazole triple therapy for Helicobacter pylori--is 5 days enough? | 1998 | Aliment. Pharmacol. Ther. | pmid:9570262 |
Dal Bo' N et al. | Low dose of clarithromycin in triple therapy for the eradication of Helicobacter pylori: one or two weeks? | 1998 | J. Gastroenterol. Hepatol. | pmid:9570242 |
Sonnenberg A et al. | Cost savings in duodenal ulcer therapy through Helicobacter pylori eradication compared with conventional therapies: results of a randomized, double-blind, multicenter trial. Gastrointestinal Utilization Trial Study Group. | 1998 | Arch. Intern. Med. | pmid:9570170 |
Hoppe JE and Bryskier A | In vitro susceptibilities of Bordetella pertussis and Bordetella parapertussis to two ketolides (HMR 3004 and HMR 3647), four macrolides (azithromycin, clarithromycin, erythromycin A, and roxithromycin), and two ansamycins (rifampin and rifapentine). | 1998 | Antimicrob. Agents Chemother. | pmid:9559823 |
Cheng KL et al. | Effect of grapefruit juice on clarithromycin pharmacokinetics. | 1998 | Antimicrob. Agents Chemother. | pmid:9559810 |
Scheen AJ | [Drug clinics. The drug of the month. Ranitidine bismuth citrate (Pylorid)]. | 1998 | Rev Med Liege | pmid:9555183 |
Iwata M et al. | [Three cases of Fitz-Hugh-Curtis syndrome detected in the early stage by abdominal ultrasonography]. | 1998 | Nippon Naika Gakkai Zasshi | pmid:9549331 |
Carnicer J | [Helicobacter pylori infection and recurrent abdominal pain in children. A proved relationship?]. | 1998 | Gastroenterol Hepatol | pmid:9549199 |
Comet R et al. | [Seven-day omeprazole, clarithromycin, and amoxicillin for the therapy of Helicobacter pylori infection]. | 1998 | Gastroenterol Hepatol | pmid:9549183 |
Lindsetmo RO et al. | Lansoprazole, amoxicillin, and clarithromycin triple therapy in vagotomized patients with dyspeptic complaints. A randomized, double-blind, placebo-controlled, clinical study without pretreatment diagnostic upper endoscopy. | 1998 | Scand. J. Gastroenterol. | pmid:9548613 |
Suzuki J et al. | Assessment of a new triple agent regimen for the eradication of Helicobacter pylori and the nature of H. pylori resistance to this therapy in Japan. | 1998 | Helicobacter | pmid:9546120 |
Treiber G et al. | Amoxicillin/metronidazole/omeprazole/clarithromycin: a new, short quadruple therapy for Helicobacter pylori eradication. | 1998 | Helicobacter | pmid:9546119 |
Oberg KC | Delayed elevation of international normalized ratio with concurrent clarithromycin and warfarin therapy. | 1998 Mar-Apr | Pharmacotherapy | pmid:9545160 |
Perng CL et al. | One-week triple therapy with lansoprazole, clarithromycin, and metronidazole to cure Helicobacter pylori infection in peptic ulcer disease in Korea. | 1998 | Dig. Dis. Sci. | pmid:9539638 |
Gisbert JP et al. | [new one-week triple therapies with metronidazole for the eradication of Helicobacter pylori: clarithromycin or amoxycillin as the second antibiotic]. | 1998 | Med Clin (Barc) | pmid:9527978 |
Kashuba AD and Amsden GW | Bronchopulmonary pharmacokinetics of clarithromycin and azithromycin. | 1998 | Antimicrob. Agents Chemother. | pmid:9527816 |
Collins LA et al. | Green fluorescent protein reporter microplate assay for high-throughput screening of compounds against Mycobacterium tuberculosis. | 1998 | Antimicrob. Agents Chemother. | pmid:9527783 |
Berquist WE | New, improved Helicobacter pylori eradication therapy in children. | 1998 | J. Pediatr. Gastroenterol. Nutr. | pmid:9523877 |
Alegre Herrera S et al. | [Clarithromycin-carbamazepine interaction: neurological symptoms and hyponatremia]. | 1998 | An Med Interna | pmid:9522506 |
Laine L and Fendrick AM | Helicobacter pylori and peptic ulcer disease. Bridging the gap between knowledge and treatment. | 1998 | Postgrad Med | pmid:9519040 |
Trivedi S et al. | Clarithromycin and digoxin toxicity. | 1998 | Ann. Intern. Med. | pmid:9518419 |
Fattorini L et al. | Activities of isoniazid alone and in combination with other drugs against Mycobacterium avium infection in beige mice. | 1998 | Antimicrob. Agents Chemother. | pmid:9517960 |
Hafner R et al. | Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers. | 1998 | Antimicrob. Agents Chemother. | pmid:9517944 |
Trevisani L et al. | A four-day low dose triple therapy regimen for the treatment of Helicobacter pylori infection. | 1998 | Am. J. Gastroenterol. | pmid:9517646 |
Adamek RJ et al. | Primary and acquired Helicobacter pylori resistance to clarithromycin, metronidazole, and amoxicillin--influence on treatment outcome. | 1998 | Am. J. Gastroenterol. | pmid:9517645 |
Bardhan KD et al. | Ranitidine bismuth citrate with clarithromycin given twice daily effectively eradicates Helicobacter pylori and heals duodenal ulcers. | 1998 | Am. J. Gastroenterol. | pmid:9517644 |
Williamson R et al. | New options in Helicobacter pylori eradication: efficacy, resistance and synergy. | 1998 | Scand. J. Gastroenterol. Suppl. | pmid:9515751 |
Moayyedi P | Amoxycillin dual therapy against Helicobacter pylori--the final nail in the coffin? | 1997 | Ital J Gastroenterol Hepatol | pmid:9513823 |
Sato K et al. | Antimicrobial activities of benzoxazinorifamycin KRM-1648, clarithromycin and levofloxacin against intracellular Mycobacterium avium complex phagocytosed by murine peritoneal macrophages. | 1998 | J. Antimicrob. Chemother. | pmid:9511040 |
Carlson LD et al. | Standardized BACTEC method to measure clarithromycin susceptibility of Mycobacterium genavense. | 1998 | J. Clin. Microbiol. | pmid:9508306 |
Rosina P et al. | Fixed drug eruption from clarithromycin. | 1998 | Contact Derm. | pmid:9506224 |
Ziering W and McElvaine P | Randomized comparison of once-daily ceftibuten and twice-daily clarithromycin in the treatment of acute exacerbation of chronic bronchitis. | 1998 Jan-Feb | Infection | pmid:9505188 |
Hocqueloux L et al. | Pulmonary Mycobacterium avium complex disease without dissemination in HIV-infected patients. | 1998 | Chest | pmid:9498982 |
Dubois A et al. | Cure of Helicobacter pylori infection by omeprazole-clarithromycin-based therapy in non-human primates. | 1998 | J. Gastroenterol. | pmid:9497216 |
Kusuhara H et al. | Evaluation of combined antibiotic-omeprazole therapies in Helicobacter pylori-infected Mongolian gerbils. | 1998 | J. Gastroenterol. | pmid:9497215 |
Payen MC et al. | [Manifestations, diagnosis and treatment of non-tuberculous mycobacterial infections in patients with HIV infection]. | 1997 | Rev Mal Respir | pmid:9496599 |
Pérez Mota A et al. | Helicobacter pylori, efficacy of the new triple therapy in six and twelve-day schedules. | 1997 | Rev Esp Enferm Dig | pmid:9494375 |
Boixeda de Miquel D | [Efficacy of the triple therapy in the eradication of H. pylori in peptic ulcer]. | 1997 | Rev Esp Enferm Dig | pmid:9494374 |
Kondoh K and Hashiba M | [Inhibitory effect of macrolide antibiotics on biofilm formation by Pseudomonas aeruginosa]. | 1998 | Nippon Jibiinkoka Gakkai Kaiho | pmid:9493436 |
Hermon-Taylor J et al. | Mycobacterium paratuberculosis cervical lymphadenitis, followed five years later by terminal ileitis similar to Crohn's disease. | 1998 | BMJ | pmid:9492675 |
Igea JM and Lázaro M | Hypersensitivity reaction to clarithromycin. | 1998 | Allergy | pmid:9491242 |
Ridgway GL et al. | The in-vitro activity of grepafloxacin against Chlamydia spp., Mycoplasma spp., Ureaplasma urealyticum and Legionella spp. | 1997 | J. Antimicrob. Chemother. | pmid:9484871 |
Hotz J | [Reflux disease of the gastrointestinal tract. Acute therapy and long-term care in daily practice. 2. Therapeutic procedure--diagnosis--therapy-diagram]. | 1997 | Fortschr. Med. | pmid:9480263 |
Cammarota G et al. | Regression of a primary gastric MALT lymphoma with extensive antrum lesions by Helicobacter pylori eradication. | 1997 | Ital J Gastroenterol Hepatol | pmid:9476192 |